This presentation material contains information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.
Hisamitsu Pharmaceutical Co., Inc.
Jul. 13th, 2023
11
Agenda
Looking back on the Q1 FY02/2024
Latest topics
Promotion of Sustainability
Consolidated P&L
Sales Results by Region
Sales Results by Product
Trends of second-generationnon-steroidalanti-inflammatory patch(Topical formulations) in Japan
Trends of non-steroidalanti-inflammatory drugs, anti-rheumatic
drugs (Systemic formulations) Market Trend in Japan 9.R&D Pipeline
2
1. Looking back on the Q1 FY02/2024(1)
Rx Business
OTC Business
Others
Mar. ・Notification of approval for manufacturing and marketing approval of APOHIDE® Lotion 20% in Japan (Primary palmar hyperhidrosis treatment drug, development code: HP-5070)
May. ・Notification of Launch of APOHIDE® Lotion 20% in Japan (Primary palmar hyperhidrosis treatment drug)
Mar. ・Launch of "Feitas®Z Dicsas® ShippuF" 7 patches in Japan
Apr. ・Launch of "SALONPAS HOT®" 3 patches in Japan
Apr. ・Feitas® TV Commercials will feature SHIGEOKA Daiki (Johnny's WEST) and IWAMOTO Hikaru (Snow Man) as image characters.
Mar. ・The Minister of Economy, Trade and Industry Award at the 31st Global Environment Awards for the Kiyohara Industrial Park SmartEnergy Project
Mar. ・Became an official partner of TEAM JAPAN (topical analgesic anti-inflammatory drugs, muscle fatigue care products, and medical supporters)
Mar. ・JLPGA Step Up Tour "Salonpas Ladies Open" Newly Announced Mar. ・Establishment of a new research base at Shonan iPark
Mar. ・Notice regarding Revision of Earnings Forecast
May. ・Salonpas® certified as the World's No. 1 OTC topical analgesic patch brand for the 7th consecutive year since 2016.
Hisamitsu Pharmaceutical certified as the holder of the world's largest share in the corresponding
market category for the 6th consecutive year since 2017.
3
1. Looking back on the Q1 FY02/2024(2)
Feitas®Z Dicsas® ShippuF
・Reduction of package material
approximately 88%
・Reduction of material waste
approximately 3.1t/year
■ Product Information
https://www.hisamitsu.info/feitas/product/26.html
Poke-SipⓇ Series
Nobinobi® Salonsip® Fit®
Nobinobi® Salonsip® Fit®α
Nobinobi® Salonsip® Fit®H
Feitas® Shippu
Feitas® Shippu Onkan
(Odorless type)
(Hot Type)
(Hot Type)
10patches 20patches 40patches
10patches 20patches
10patches 20patches
10patches
10patches
4
1. Looking back on the Q1 FY02/2024(3)
SALONPAS HOT®
・Reduction of package material approximately 40%
・Reduction of material waste approximately 0.22t/year
■ Product Information
https://www.salonpas.jp/lineup/salonpas_hot.html
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 13 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 July 2023 06:09:10 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
